All In Biotech

Drug Trial Radar · NCT06149494

RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection

A Trial in Participants With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate the Impact of Vapendavir on the Development of Lower Respiratory Tract Symptoms Following Rhinovirus Challenge

Last checked: Nov 19, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Nov 20, 2023

Primary completion

Mar 30, 2025

Study completion Mar 30, 2025

Sponsor

Lead sponsor
Altesa Biosciences, Inc.Industry
Sponsor type
Industry
Collaborators
Virtus Respiratory Research
First posted
Nov 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Vapendavir (VPV) is a drug being developed to treat human rhinovirus (RV) infection, one virus responsible for the common cold. Vapendavir prevents the virus from entering cells and making more infectious copies of itself. A study is being planned to investigate VPV in patients with chronic obstructive pulmonary disease (COPD, a lung disease making it difficult to breathe) who develop a rhinoviral infection; however, VPV has not been approved for use in treating any indication (disease) by the FDA or any other global regulatory agency. Therefore, VPV is considered investigational, and the study doctor is conducting this investigational research study. Safety will be monitored throughout the entire study.

Conditions

  • COPD Exacerbation Acute
  • COPD With Acute Lower Respiratory Infection
  • Rhinovirus
  • Virus Diseases
  • Virus Infection, RNA
  • Enterovirus
  • Enterovirus Infections
  • Rhinovirus Infection
  • Infection Viral
  • Respiratory Complication
  • Respiratory Disease
  • Respiratory Tract Infections
  • Respiratory Tract Diseases
  • Respiratory Viral Infection
  • Upper Resp Tract Infection
  • Upper Respiratory Tract Infections
  • Upper Respiratory Disease
  • Upper Respiratory Disorder
  • Upper Respiratory Disease, Acute
  • Upper Respiratory Infection Viral
  • Infections, Respiratory
  • Infections
  • Copd
  • Viral Infection
  • Emphysema or COPD
  • Lower Respiratory Disease
  • Lower Respiratory Disorder
  • Lower Respiratory Tract and Lung Infections
  • Pulmonary Disease
  • Pulmonary Disease, Chronic Obstructive
  • Respiratory Disease Chronic
  • Lung Diseases
  • Lung Disease Chronic
  • Obstructive Pulmonary Disease
  • Chronic Lower Respiratory Diseases
  • Chronic Respiratory Disease

Interventions

  • VapendavirDrug

    Participants randomized to the experimental cohort will be administered Vapendavir.

  • PlaceboDrug

    Participants randomized to the placebo cohort will be administered placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak change from baselineTime frame: From Baseline Visit through Follow-Up Visit, up to 7 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St. Mary's Hospital - Imperial College Respiratory Research Unit (ICRRU)

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.